Home   Home E-mail   E-Mail SiteMap   Site Map
Medicalook
SEARCH

  http://www.medicalook.com
    ARTICLES HUMAN ANATOMY DISEASES LIST DRUGS LIST MEDICAL TESTS

DISEASES LIST
.: Addiction
.: Adhd
.: Allergies
.: Bacterial infections
.: Birth control
.: Blood disorders
.: Bone diseases
.: Cancer
.: Diabetes
.: Digestive system
.: Ear infections
.: Eye diseases
.: Fever
.: Hair loss
.: Heart diseases
  .: Acute Coronary Syndrome
  .: Angina pectoris
  .: Aortic stenosis
  .: Atrial fibrillation
  .: Blood clots
  .: Chest pain
  .: Congestive heart failure
  .: Coronary heart disease
  .: Endocarditis
  .: Heart attack
  .: High blood pressure
  .: Hypertension
  .: Hypertrophic cardiomyopathy
  .: Intermittent claudication
  .: Irregular heartbeat
  .: Ischemic heart disease
  .: Myocardial infarction
  .: Vasculitis
  .: Ventricular arrhythmia
  .: Ventricular fibrillation
  .: Ventricular tachycardia
.: Hormonal disorders
.: Infectious diseases
.: Joint pain
.: Lower cholesterol
.: Lung diseases
.: Men's health
.: Mental health
.: Mouth diseases
.: Neurological disorders
.: Nutritional supplement
.: Pain relief
.: Parasitic diseases
.: Skin diseases
.: Sleep disorders
.: Std
.: Urinary tract infections
.: Viral infections
.: Weight loss
.: Women's health

ADVERTISING

Eprosartan

E-mail this E-mail this     Print Print this     Save for later ?    


Eprosartan

Eprosartan review



buy Eprosartan Buy Eprosartan
Eprosartan is classified as an angiotensin II receptor antagonist drug that is used for treating conditions such as high blood pressure. Eprosartan’s action focuses on the rennin-angiotensin system by decreasing the total peripheral resistance in two ways. It first blocks angiotensin II binding in AT1 receptors in the vascular smooth muscles which causes vascular dilatation. Secondly, it inhibits the production of sympathetic norepinephrine which further reduces the patient’s blood pressure.

As compared with the other angiotensin II receptor antagonists, eprosartan has been reported to be better tolerated than its counterpart enalapril, especially among the geriatric population.

Eprosartan is marketed as Teveten by Abbott Laboratories in the United States. It is sometimes paired with hydrochlorothiazide and marketed as Teveten HCT or Teveten Plus. Teveten is indicated for the treatment of hypertension or high blood pressure.

The usual dose recommended in eprosartan administration is 600 mg once daily, if used as a single therapy drug (monotherapy) with patients found out to be non-volume depleted. Teveten may be administered once or twice daily with total daily doses that range from 400 – 800 mg. The maximum reduction in blood pressure may be achieved by most patients if eprosartan is taken within two to three weeks.

Side effects of eprosartan use may vary from patient to patient. However, most commonly reported side effects include dizziness, joint pains (athralgia), rhinitis or inflamed nose linings causing runny or blocked noses, flatulence or excessive gas in the stomach, increased levels of triglycerides in the blood stream (hypertriglyceridemia), hyperkalemia or an increase in potassium levels in the blood, headaches, nausea, vomiting, weakness, swelling of the lips or tongue, and low blood pressure.

Teveten has been found to be safely co-administered with other anti-hypertensive drugs when additional effects of lowering blood pressure is required, such as those of thiazide diuretics or calcium channel blockers. Discontinuing eprosartan therapy has not been reported to a rebound in blood pressure increase.

Eprosartan/Teveten must be taken with a full stomach. Eprosartan is contraindicated in patients with hypersensitivity to the drug or its components. Dizziness and/or nausea may occur when taking eprosartan. Caution must be exercised when performing tasks that require focus and attention such as driving or machine operation.

As eprosartan works on the blood, people with ailments in the kidneys or kidney function must undergo regular blood tests to check the levels of creatinine and potassium in their bloodstream while undergoing eprosartan therapy.

Caution must be exercised when taking eprosartan if patients are 75 years or older, have decreased kidney functions, have any history of heart or blood vessel problems, and low fluid volumes or salt levels in the body due to diet, diarrhea or vomiting.

Eprosartan is not to be used with patients suffering from severe liver impairment, severe heart and blood vessel problems. Pregnant women, or women planning to become pregnant must first consult a physician prior to eprosartan administration. Nursing mothers must also consult a doctor before taking eprosartan. The potential benefits the drug must be weighed against the risks it may pose to the fetus and the nursing infant. Eprosartan may be harmful to children because of its preservative – alcohol.

Eprosartan has the following structural formula:

Chemical structure of eprosartan


• Molecular formula of eprosartan is C23H24N2O4S
• Chemical IUPAC Name is 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-yl-prop-1-enyl)-imidazol-1-yl]methyl]benzoicacid
• Molecular weight is 424.514 g/mol
Eprosartan available : 400mg tablets and 600mg tablets

Brand name(s): Teveten, Teveten Plus

  Your Eprosartan review
©2007-2014 Medicalook.com All rights reserved About Us | Terms of Use | Privacy Statement